A signature of 17 immune-related gene pairs predicts prognosis and immune status in HNSCC patients

Jiang, Pan; Li, Yanli; Xu, Zheng; He, Shengteng

doi:10.1016/j.tranon.2020.100924

Cited by 16 publications

(13 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gene pair is an expression of the targeted and reference genes from the one sample. Signatures that resemble gene pairs have been used in prognostic evaluations of various cancers [30] , [31] , [32] , [33] . Moreover, the concordance between the 1p/19 codeletion-associated immune prognostic signature developed in our earlier study [6] and the current gene pairs signature was greatly improved than that of the EORTC and RTOG criteria [5] .…”

Section: Discussionmentioning

confidence: 99%

A novel tailored immune gene pairs signature for overall survival prediction in lower-grade gliomas

Pan

Wang

Liu

et al. 2021

Translational Oncology

View full text Add to dashboard Cite

Highlights The Immune-related gene pairs (IRGPs) pronostic signature for LGG is correlated with immune cells infiltration. WGCNA presented a gene set correlating with immune cells infiltration and genes co-expression relationships were visualized. The nomogram constrcted by three IRGPs and clinical factors is a novel tailored tool for individual-level prediction.

show abstract

Section: Discussionmentioning

confidence: 99%

A novel tailored immune gene pairs signature for overall survival prediction in lower-grade gliomas

Pan

Wang

Liu

et al. 2021

Translational Oncology

View full text Add to dashboard Cite

show abstract

“…While the presence of abundant tumor infiltrating lymphocytes is generally associated with improved prognosis ( Figure 3 ), differences have been reported according to anatomic subsite, tumor compartment and depending on the HPV status [ 28 ]. Numerous groups addressed the prognostic value of immune-related gene signatures in primary HNSCC and provided growing evidence for a pivotal correlation between molecular immune subgroups and prognostic risk assessment for HNSCC patients [ 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 ]. Though most studies made use of similar transcriptome and clinical data, in particular from TCGA-HNSC the diversity of clinically-relevant immune-related gene signatures is quite high with only minor or no overlap in selected candidate genes.…”

Section: Immune-related Gene Signaturesmentioning

confidence: 99%

Immune-Related Mutational Landscape and Gene Signatures: Prognostic Value and Therapeutic Impact for Head and Neck Cancer

Feng

Heß

2021

Cancers

View full text Add to dashboard Cite

Immunotherapy by immune checkpoint inhibition has become a main pillar in the armamentarium to treat head and neck cancer and is based on the premise that the host immune system can be reactivated to successfully eliminate cancer cells. However, the response rate remains low and only a small subset of head and neck cancer patients achieves a durable clinical benefit. The availability of multi-omics data and emerging computational technologies facilitate not only a deeper understanding of the cellular composition in the tumor immune microenvironment but also enables the study of molecular principles in the complex regulation of immune surveillance versus tolerance. These knowledges will pave the way to apply immunotherapy more precisely and effectively. This review aims to provide a holistic view on how the immune landscape dictates the tumor fate and vice versa, and how integrative analysis of multi-omics data contribute to our current knowledge on the accuracy of predictive biomarkers and on a broad range of factors influencing the response to immunotherapy in head and neck cancer.

show abstract

“…However, most patients of LUAD are still not sensitive to immune checkpoint inhibitors ( Wang et al, 2020 ). Recent studies have shown that the remodeling of TME plays an important role in the development of LUAD, weakening the response of LUAD patients to immunotherapy ( Jiang et al, 2021 ). Thus, the identification of essential genes that could affect the TME is urgently needed.…”

Section: Introductionmentioning

confidence: 99%

TPD52L2 Is a Prognostic Biomarker and Correlated With Immune Infiltration in Lung Adenocarcinoma

et al. 2021

View full text Add to dashboard Cite

Tumor protein D52-like 2 (TPD52L2) belongs to the members of the TPD52 family. TPD52L2 was reported to regulate proliferation and apoptosis in cancer cells. However, its role in lung adenocarcinoma (LUAD) was uncertain. We evaluated the expression, methylation, copy number alteration, and prognostic significance of TPD52L2 using RNA-seq data from The Cancer Genome Atlas (TCGA). Enrichment analysis of TPD52L2 was conducted using the R package “clusterProfiler.” We further assessed the association between TPD52L2 and immune cell infiltration level, immunosuppressive genes, and tumor mutational burden (TMB). The difference of gene mutant frequency in high- and low-TPD52L2 groups was also analyzed. The results showed that TPD52L2 was over-expressed and predicted worse survival status in LUAD. We also found that TPD52L2 expression was positively associated with the infiltration levels of immunosuppressive cells, such as regulatory T cells (Tregs) and tumor-associated macrophages (TAMs), and negatively correlated with immune killer cells, such as CD8+ T and NK cells in pan-cancer, including LUAD. In addition, TPD52L2 expression was associated with immunosuppressive genes and TMB. High expression of TPD52L2 was with more mutant frequency of TP53. In summary, our results show that TPD52L2 is an oncogene and a potential prognostic biomarker in LUAD. High TPD52L2 expression is a possible indicator of immune infiltration and associated with tumor immunosuppressive status in LUAD.

show abstract

A signature of 17 immune-related gene pairs predicts prognosis and immune status in HNSCC patients

Cited by 16 publications

References 40 publications

A novel tailored immune gene pairs signature for overall survival prediction in lower-grade gliomas

A novel tailored immune gene pairs signature for overall survival prediction in lower-grade gliomas

Immune-Related Mutational Landscape and Gene Signatures: Prognostic Value and Therapeutic Impact for Head and Neck Cancer

TPD52L2 Is a Prognostic Biomarker and Correlated With Immune Infiltration in Lung Adenocarcinoma

Contact Info

Product

Resources

About